Thymosin Alpha-1 Half-Life & Stability
Part of the full Thymosin Alpha-1 guide - a immunomodulatory thymic peptide reference compound, identity-verified with a COA on every vial.
In brief
The entry provides no Thymosin alpha-1-specific pharmacokinetic numbers, no measured half-life, and no quantitative degradation data, so this section combines the peptide-specific structural facts that are given with general peptide-class stability principles, clearly flagging which is which. What the data do give are structural determinants of handling: a defined molecular weight (3108.32 g/mol), an N-terminal acetylation, the absence of any cysteine or disulfide bond, and a glutamate/aspartate-rich linear sequence. These features inform reasoning about stability at the bench even though no kinetic half-life is reported.
The detail
A closer look
01
Structural stability features documented in the entry
Two structural facts in the entry bear directly on stability reasoning. First, the N-terminus is acetylated (the sequence begins Ac-Ser-), and N-terminal acetylation is a capping modification that, as a general peptide-chemistry principle, removes the free alpha-amino group; this is a peptide-specific structural fact from the entry, while the general consequence for handling is class-level reasoning. Second, the sequence contains no cysteines and no disulfide bonds, so there is no intramolecular disulfide that could scramble or reduce, eliminating one common oxidative-degradation pathway that complicates storage of cysteine-bearing peptides. Both points are stated as structural facts in the entry; their stability implications are framed here as general principles, not as measured Thymosin alpha-1 data.
02
General peptide-class storage and degradation principles
Because no peptide-specific kinetic data are provided, storage guidance defaults to general peptide-class practice: lyophilized peptide is the most stable form and is kept cold; reconstituted aqueous stock is less stable than the dry powder and is therefore aliquoted into single-use volumes, labeled with concentration and date, and stored cold to limit repeated freeze-thaw cycling. These are general handling principles applicable across research peptides, stated as such here because the entry supplies no Thymosin alpha-1-specific shelf-life, in-solution half-life, or temperature-stability measurements. No in-vivo clearance or circulating half-life value is claimed because none is present in the source data.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. Thymosin Alpha-1 is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.